Industry
Nuvelution TS Pharma, Inc.
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
Failure Rate
33.3%
1 terminated/withdrawn out of 3 trials
Success Rate
66.7%
-19.8% vs industry average
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
150%
3 of 2 completed trials have results
Key Signals
3 with results
Enrollment Performance
Analytics
Phase 3
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 3(2)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT03571256Phase 3Completed
A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
Role: collaborator
NCT03567291Phase 3Terminated
Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
Role: collaborator
NCT03452943Phase 2Completed
Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
Role: collaborator
All 3 trials loaded